palmitoylcarnitine has been researched along with Disease Exacerbation in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Askevold, ET; Aukrust, P; Berge, RK; Bjørndal, B; Dahl, CP; Gullestad, L; Nymoen, SH; Svardal, A; Ueland, T; Øie, E | 1 |
| Grunnet, N; Hansen, LL; Jelnes, P; Jørgensen, W; Quistorff, B; Rud, KA | 1 |
2 other study(ies) available for palmitoylcarnitine and Disease Exacerbation
| Article | Year |
|---|---|
Disturbed carnitine regulation in chronic heart failure--increased plasma levels of palmitoyl-carnitine are associated with poor prognosis.
Topics: Adult; Aged; Biomarkers; Carnitine; Chronic Disease; Disease Progression; Female; Heart Failure; Humans; Male; Middle Aged; Palmitoylcarnitine; Prognosis | 2013 |
Progression of type 2 diabetes in GK rats affects muscle and liver mitochondria differently: pronounced reduction of complex II flux is observed in liver only.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Progression; Electron Transport Complex II; Lipid Peroxidation; Male; Mitochondria, Liver; Mitochondria, Muscle; Oxygen Consumption; Palmitoylcarnitine; Phosphorylation; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Severity of Illness Index; Succinate Dehydrogenase | 2012 |